Evidence map›Paper›PMID 42345078›Full record

ArticleACS infectious diseases2026

Using Unbiased Chemical Proteomics Approaches to Explore the Target Landscape of the Resistance Refractory 7-Azaindole MMV022224 in

Aisha J Syed, Rachel Milne, Victoriano Corpas-Lopez, Gourav Dey, Nonlawat Boonyalai, Richard J Wall, Natalie Wiedemar, Lukas Montejo, Flore Nardella, Kathryn J Wicht and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Aisha J SyedDrug Discovery Unit, Division of Drug Discovery, Faculty of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom.
Rachel MilneDrug Discovery Unit, Division of Drug Discovery, Faculty of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom.
Victoriano Corpas-LopezDrug Discovery Unit, Division of Drug Discovery, Faculty of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom.
Gourav DeyDrug Discovery Unit, Division of Drug Discovery, Faculty of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom.
Nonlawat BoonyalaiDivision of Biological Chemistry and Drug Discovery, Faculty of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom.
Richard J WallDrug Discovery Unit, Division of Drug Discovery, Faculty of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom.
Natalie WiedemarDrug Discovery Unit, Division of Drug Discovery, Faculty of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom.
Lukas MontejoDivision of Molecular Microbiology, Burnett School of Biomedical Sciences, University of Central Florida, 12722 Research Parkway, Orlando, Florida 32826, United States.
Flore NardellaDivision of Molecular Microbiology, Burnett School of Biomedical Sciences, University of Central Florida, 12722 Research Parkway, Orlando, Florida 32826, United States.
Kathryn J WichtHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0001-6145-9956
Charisse Flerida A PasajeDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
John OkomboDepartment of Microbiology & Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States.
Jacquin C NilesDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID 0000-0002-6250-8796
David A FidockDepartment of Microbiology & Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States.
Marcus C S LeeDivision of Biological Chemistry and Drug Discovery, Faculty of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom.
Debopam ChakrabartiDivision of Molecular Microbiology, Burnett School of Biomedical Sciences, University of Central Florida, 12722 Research Parkway, Orlando, Florida 32826, United States.
Stephen PattersonDrug Discovery Unit, Division of Drug Discovery, Faculty of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom.
Susan WyllieDrug Discovery Unit, Division of Drug Discovery, Faculty of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom.ORCID 0000-0001-8810-5605

Funding

Plasmodium Protein Kinase Focused Antimalarials DiscoveryR01AI172066 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI DEBOPAM CHAKRABARTI, NATHANAEL Schiander GRAY · 2022 to 2026
$3.9M
New tools for antimalarial target identificationR01AI143521 · NIAID · UNIVERSITY OF CAPE TOWN · PI WICHT, KATHRYN JEAN · 2019 to 2023
$709k
Bill & Melinda Gates Foundation INV-004096Bill & Melinda Gates Foundation INV-007840Bill & Melinda Gates Foundation INV-026505Bill & Melinda Gates Foundation INV-033538NIAID NIH HHS R01 AI143521NIAID NIH HHS R01 AI172066
6 · The paper itself

Abstract

Current standard of care, artemisinin-based therapies for malaria, are threatened by emerging drug resistance. Developing antimalarials with novel mechanisms of action and low propensity for resistance is of the highest priority. Here, we explore the target landscape of MMV022224, a promising antimalarial that is active against multiple stages of

Indexed as

AntimalarialsDrug ResistanceIndolesPlasmodium falciparumProteomicsHumansMalaria, FalciparumProtozoan ProteinsAntimalarialsIndolesProtozoan Proteinsantimalarial drug discoverychemical biologychemical pulldownisothermal TPPPlasmodiumtarget deconvolution

Identifiers

PMID42345078
PMCPMC13366577

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.